Next Article in Journal
Antimicrobial Activity of Gemini Surfactants with Azapolymethylene Spacer
Next Article in Special Issue
Macrocyclic Chelates Bridged by a Diaza-Crown Ether: Towards Multinuclear Bimodal Molecular Imaging Probes
Previous Article in Journal
Anti-Inflammatory Effects of a Cordyceps sinensis Mycelium Culture Extract (Cs-4) on Rodent Models of Allergic Rhinitis and Asthma
Previous Article in Special Issue
Modulating the Properties of Fe(III) Macrocyclic MRI Contrast Agents by Appending Sulfonate or Hydroxyl Groups
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Functionalization of Magnetic Nanoparticles by Folate as Potential MRI Contrast Agent for Breast Cancer Diagnostics

1
Department of Biotechnology, Faculty of Biological Sciences and Technology, University of Isfahan, Isfahan 81746-73441, Iran
2
Faculty of Physics, University of Isfahan, Isfahan 81746-73441, Iran
3
Sabanci University Nanotechnology Research and Application Center (SUNUM), Tuzla, 34956 Istanbul, Turkey
4
Department of Basic Sciences, Faculty of Veterinary Medicine, University of Tabriz, Tabriz 51666-16471, Iran
5
Istituto Italiano di Tecnologia, Centre for Micro-BioRobotics, viale Rinaldo Piaggio 34, 56025 Pontedera, Pisa, Italy
6
Department of Medical Nanotechnology, Faculty of Advanced, Technologies in Medicine, Iran University of Medical Sciences, Tehran 14496-14535, Iran
*
Authors to whom correspondence should be addressed.
Molecules 2020, 25(18), 4053; https://doi.org/10.3390/molecules25184053
Submission received: 8 July 2020 / Revised: 1 September 2020 / Accepted: 3 September 2020 / Published: 4 September 2020
(This article belongs to the Special Issue Recent Advances on MRI Contrast Agents)

Abstract

:
In recent years, the intrinsic magnetic properties of magnetic nanoparticles (MNPs) have made them one of the most promising candidates for magnetic resonance imaging (MRI). This study aims to evaluate the effect of different coating agents (with and without targeting agents) on the magnetic property of MNPs. In detail, iron oxide nanoparticles (IONPs) were prepared by the polyol method. The nanoparticles were then divided into two groups, one of which was coated with silica (SiO2) and hyperbranched polyglycerol (HPG) (SPION@SiO2@HPG); the other was covered by HPG alone (SPION@HPG). In the following section, folic acid (FA), as a targeting agent, was attached on the surface of nanoparticles. Physicochemical properties of nanostructures were characterized using Fourier transform infrared spectroscopy (FT-IR), transmission electron microscopy (TEM), and a vibrating sample magnetometer (VSM). TEM results showed that SPION@HPG was monodispersed with the average size of about 20 nm, while SPION@SiO2@HPG had a size of about 25 nm. Moreover, HPG coated nanoparticles had much lower magnetic saturation than the silica coated ones. The MR signal intensity of the nanostructures showed a relation between increasing the nanoparticle concentrations inside the MCF-7 cells and decreasing the signal related to the T2 relaxation time. The comparison of coating showed that SPION@SiO2@HPG (with/without a targeting agent) had significantly higher r2 value in comparison to Fe3O4@HPG. Based on the results of this study, the Fe3O4@SiO2@HPG-FA nanoparticles have shown the best magnetic properties, and can be considered promising contrast agents for magnetic resonance imaging applications.

1. Introduction

Because of their unique physicochemical properties, nanoparticles (NP) have broad applications in a variety of biomedical researches, like implants [1], drug delivery systems [2], tissue engineering [3], and infection therapy [4]. One of the significant applications of nanomaterials in medicine is the timely detection and treatment of cancer [5]. Different nanoprobes such as quantum dots have been developed for the early diagnosis of breast cancer, and this requires understanding the distribution and removal of nanoparticles at the breast tumor site [6]. One of the potential applications of NP is in diagnostic medicine, particularly for magnetic resonance imaging (MRI).
Briefly, MRI is a noninvasive imaging modality that, by exposing the hydrogen protons to an external magnetic field (B0), leads to aligning some parts of protons towards B0 direction and then rotation around it. Then, radiofrequency (RF) waves apply in the equal frequency with the precession of the protons, resulting in the RF pulse energy adding to the protons. Subsequently, when the RF pulse is turned off, protons flip back to the original state and generate a radiofrequency signal in a process called “relaxation” [7,8,9].
Two kinds of relaxation processes exist; namely, longitudinal or T1 relaxation, also called spin-lattice relaxation, and transverse or T2 relaxation, referred to as spin-spin relaxation. The former refers to the process through which the net longitudinal magnetization goes back to its earliest maximum value parallel to the magnetic field, as described in the following equation [8]:
M z = M z , 0 ( 1 e t T 1 )
where Mz,0 refers to the magnetization in an equilibrium state, and T1 stands for the time for Mz to reach 63% of the original magnetization after the application of the RF pulse.
The latter is the process referring to the transverse components of magnetization decay or dephases, as described in the following equation [8]:
M x y = M x y , 0 e t T 2
in which Mxy illustrates the decay of magnetization, Mxy,0 depicts the initial transverse magnetization, and T2 shows the time for transversal magnetization dropping to 37%.
Although MRI has gained much publicity in medicine diagnostics, there are some drawbacks associated with it. One of the most important ones is low sensitivity that reduces its potential in molecular level detection [10]. To overcome this restriction, increasing contrast between healthy and diseased tissues is of great importance.
Typically, elements like gadolinium, iron, and manganese that possess unpaired electron spins are referred to as T1 contrast agents. They could increase the T1 relaxation time via increasing the signal intensity, thus causing a positive contrast in images. On the other hand, superparamagnetic iron oxide nanoparticles (SPIONs) decrease the signal intensity via the reduction of T2 relaxation time, resulting in images with negative contrast [11,12,13,14]. Gadolinium is the most widely used contrast agent in MRI, which has many limitations, the most important of which are its cytotoxicity and non-biodegradability. Recently, SPIONs have attracted more attention due to their effectiveness at low concentration, biocompatibility, and easy functionalization that make them suitable alternatives for gadolinium in MRI [15,16].
Apart from their use as MRI contrast agents, iron oxide nanoparticles have several other potential applications, like drug delivery vehicle, cell tracking, tissue engineering, separation of biomolecules, and immobilization of enzymes or proteins in biomedical engineering [17]. However, there are obstacles and challenges for using SPIONs, including their tendency to aggregation and the protein corona effect [10,11,12,14]. One of the most prevalent approaches used to meet these obstacles is coating the surface of nanoparticles with polymers [18,19].
Hyperbranched polyglycerol (HPG) is an amphiphilic biocompatible polyether polyol with a high degree of branching, a dense structure, and a large number of terminal hydroxyl groups which can provide a broad area for encapsulation of different types of drugs and attachment of targeting molecules. Coating the nanoparticles with HPG provides them with suitable properties, such as increasing their water solubility, biocompatibility, and protein resistance ability, which are comparable to polyethylene glycol (PEG) [20,21]. Moreover, HPG polymers possess high thermal and oxidative stability [22,23].
One of the drawbacks of nanocarriers is their cytotoxicity against normal cells. This problem can be overcome using biocompatible polymers [24,25]. Furthermore, coating nanoparticles can delay their clearing from the body, and improve stability [26]. Silica is extensively used for coating nanoparticles to, in one hand, prevent their aggregation, and on the other hand, support against oxidation. It is held that silica can promote the biocompatibility of nanoparticles. The interesting point is that silica is has a high affinity for binding into surface of nanoparticles [27]. The recently published articles have also confirmed the aforementioned statements, and benefits of using silica for coating nanoparticles [28].
In this research, the impact of different coatings on the r 2 relaxivity of MR imaging of iron oxide nanoparticles was investigated. For this purpose, iron oxide magnetic nanoparticles were synthesized using the polyol method. Next, for a comparison of coating effects, synthesized nanoparticles were coated with HPG and SiO2-HPG. Then, folic acid as targeting ligand was conjugated in a covalent bond to the terminal hydroxyl groups of coating nanoparticles. Different types of physicochemical analyses (like Fourier transform infrared spectroscopy (FT-IR), transmission electron microscopy (TEM), and vibrating sample magnetometer (VSM)) were used for the characterization of the nanoparticles. Moreover, the cytotoxicity of nanoparticles was determined using MTT colorimetric assay. Finally, the differences between the magnetic properties of the coated nanoparticles (with/without targeting agent) were investigated via MRI analysis.

2. Results

2.1. Synthesis and Characterization of Nanoparticles

Fe3O4 nanoparticles were synthesized with success by using the polyol method, and then they were coated with SiO2 and HPG. The changes that occurred in the chemical structure of the nanoparticles were characterized by FT-IR spectroscopy (Figure 1 and Figure 2). Based on the result in Figure 1, the absorption peak at about 585 cm−1 belongs to the stretching vibration of Fe-O bonds in Fe3O4 nanoparticles, which could confirm the presence of Fe as the essential element in the nanoparticles. The characteristic band at around 1115–1050 cm−1 is associated with the C-O-C stretching, which could also reveal the conjugation of TREGs as an organic component on the particles surface (Figure 1a) [29,30,31].
Figure 1b illustrates the FTIR spectrum of nanoparticles coated by hyperbranched polyglycerol. The broad band at 3400 cm−1 is associated with the stretching vibration of the O-H bond, and the split peaks between 2800–2900 cm−1 belong to the C-H stretching (symmetric and asymmetric) of the polyglycerol. Moreover, the bands at around 1300–1500 cm−1 are associated with the bending vibration of the CH2 Groups. These results approve the polymerization of monomers on the surface of nanoparticles [16,21,30,32].
Figure 1c shows the FTIR result of Fe3O4 @HPG-FA nanoparticles. The intense peaks at 1400 and 1650 cm−1 correspond to the p-amino benzoic acid moieties and aromatic ring stretch of FA pteridine ring. Furthermore, significant broadening peaks at 1620 cm−1 and 1650 cm−1 represent the N-H groups of FA components, confirming the emergence of targeted SPION@HPG with FA [33,34].
In Figure 2a, the band at around 590 cm−1 is attributed to the vibration of the Fe-O bond, which shows the presence of Fe3O4 components. In addition, the bonds at about 1089 cm−1 and 806 cm−1 are associated with the Si-O vibration, revealing the presence of the SiO2 shell. As depicted in Figure 2b, the absorbance peaks at around 3435 cm−1 and 1080 cm−1 confirm the presence of HPG on the surface of nanoparticles , and they are attributed to the OH bond and C-O-C ether stretch bond, respectively [20,35].
The FTIR spectra of the FA grafted Fe3O4@SiO2@HPG nanoparticles illustrate peaks at 1610 and 1410 cm−1, which correspond to the aromatic ring stretch of pteridine ring and p-amino benzoic acid moieties of FA (Figure 2c). A significant broadening peak at 1610 cm−1 also corresponds to the ester linkage that is formed between folic acid and the hydroxyl groups. Moreover, the strong band at around 2912 cm−1 corresponds to the CH2 stretching vibrations [34,36,37].
Figure 3 shows the results of DLS analysis of synthesized and functionalized iron oxide nanoparticles after each step of surface modification. It can be seen that the synthesized Fe3O4 nanoparticles have a narrow size distribution with a mean of ~55 nm, whereas after each step of functionalization, the size increased due to the presence of new layers. In agreement with the literature, the size of the modified iron oxide is increased due to the fact that coating bring new layers to the surface of magnetic nanoparticles; accordingly, the size is enhanced [38,39].
The size and core-shell structure of nanoparticles were characterized by ultra-high-resolution transmission electron microscopy. For this test, Fe3O4, Fe3O4@HPG, Fe3O4@SiO2, Fe3O4@SiO2@HPG, and Fe3O4@SiO2@HPG-FA were characterized by TEM, as the results show in (Figure 4). In agreement with other literature studies [40,41], there is a difference between DLS and TEM sizes measurements which are normally attributed to the fundamental difference between intensity and number-weighted particle size distributions, and the differences between the dry and hydrodynamic radius of particles.
As is evident from TEM images, Fe3O4 nanoparticles (Figure 4a) have a spherical shape with a particle size of about 10 nm. Since the HPG cannot be observed in the TEM images, the size of HPG-grafted Fe3O4 nanoparticles is the same as that of bare nanoparticles. However, it could be seen that HPG coating positively affects the distribution of nanoparticles (Figure 4b). The Fe3O4@SiO2 nanoparticles show a distinct core-shell structure, and the size that is deduced from the TEM image (Figure 4c) is around 20 nm, which is smaller than Fe3O4@SiO2@HPG, with a size about 30 nm. From TEM results, we can reach the conclusion that the HPG coating conceals one core of Fe3O4, while several Fe3O4 cores are covered by silica coating, which leads to the formation of semi-composite structures.
It has been reported that polyglycerol can prevent the aggregation and enhance the stability of iron oxide nanoparticles, since these coatings have high hydrophilicity. Such stability (e.g., stabilizing the nanoparticles for about 2 months) has been shown in previous literature [38,39].

2.2. MTT Assay

One of the most common tests used for the assessment of the impact of foreign materials on the viability of cells is MTT assay, which is based on the enzymatic reduction of MTT salt to the purple formazan brought about by the mitochondria of viable cells [33,42]. In this research, the impact of cytotoxicity of various concentrations of nanoparticles on the viability of the MCF-7 cell line was evaluated by MTT assay for two days, and the results of this test are shown in Figure 5. As is clear in the figures, both of the polymeric coated nanoparticles (with or without folic acid) have no significant effect on the viability of the cells. Moreover, the viability of cells exposed by the targeted samples was a little higher than the non-targeted ones. These results confirm the cytocompatibility of this carrier, which is a critical factor for utilizing the nanocarriers in vivo. Based on the literature, this feature is due to the presence of polyglycerol, which could provide high biocompatibility for nano drug delivery systems [43,44].

2.3. Value Stream Mapping (VSM)

The magnetic properties of Fe3O4, Fe3O4@HPG, Fe3O4@HPG-FA, Fe3O4@SiO2@HPG, and Fe3O4@SiO2@HPG-FA were measured at room temperature by employing VSM (Figure 6). As can be seen, all magnetization curves are s-shaped over the applied magnetic field, confirming that they all have superparamagnetic behavior. The saturation magnetization (Ms) of Fe3O4 nanoparticles was decreased from 64.84 to 33.86, 25.80, 10.77, and 1.66 emu/g−1, when SiO2@HPG, SiO2@HPG-FA, HPG, and HPG-FA were grafted to them [16,45]. These results reveal that HPG coating could decrease Ms of nanoparticles more than SiO2@HPG coating, which may be due to its longer polymerization time leading to the production of a much thick layer on the surface of magnetic nanoparticles. By combing the results of VSM with TEM results, it could be said that Fe3O4@HPG nanoparticles contain one core of magnetic nanoparticle covered by a layer of branched polyglycerol. In contrast, Fe3O4@SiO2@HPG nanoparticles are composed of a composite of some magnetic nanoparticles dispersed in the SiO2 matrix and then covered by HPG. This event also could affect the magnetization property of the nanoparticles, leading to a reduction in the amount of magnetic saturation. Ms of about 7–22 emu/g−1 is usually adapted for biomedical and bioengineering applications; therefore, the Fe3O4@SiO2@HPG nanoparticles with higher Ms are acceptable for bio applications.

2.4. MR Imaging of Cells after They Are Incubated by Nanoparticles

The MRI was employed in order to evaluate the impact of coating on magnetic behavior of the nanoparticles used as contrast agent. For this test, Fe3O4@SiO2@HPG and Fe3O4@HPG with and without FA were used, and the results are described in Figure 7. According to this Figure, the MR signal intensity of the nanoparticles had a relationship with different concentrations of samples, so that by increasing the concentrations of nanoparticles inside the MCF-7 cells, the MR signal that is associated with the T2 relaxation time is significantly decreased, leading to a negative contrast in T2-weighted images.
The results revealed that due to their low magnetic saturation, HPG coated nanoparticles have low amounts of 1/T2 (0.5 and 0.7 for nanoparticles without and with FA, respectively), and are not suitable for MRI contrast agents (Figure 8a); while, by changing the coating of nanoparticles, the amounts of 1/T2 also changed, so that it increased from 4 S−1 for Fe3O4@SiO2@HPG to 12 S−1 for Fe3O4@SiO2@HPG-FA (Figure 8b). Generally, T2 measurement of the samples indicated that the relaxation times (1/T2) increased much faster for nanoparticles targeted with folic acid than for those not targeted.
The results of r 2 of different nanoparticles are listed in Table 1. Based on the results in Table 1, SiO2@HPG coated nanoparticles have higher r 2 in contrast to HPG one. Moreover, targeted samples have significantly higher r 2 values in comparison to non-targeted ones due to the presence of high amounts of folate receptors on the surface of the MCF-7 cell line. When FA conjugated to Fe3O4@SiO2@HPG, the r 2 value was increased from 8.87 to 23.25 mM−1S−1 that confirmed the targeting role of FA. The results reveal a preferential uptake of Fe3O4@SiO2@HPG-FA nanoparticles by the cells overexpressing the folate receptor [46,47]. Furthermore, Fe3O4@SiO2@HPG-FA targeted nanoparticles have r 2 23.25 mM−1S−1, which is higher than Fe3O4@HPG-FA with r 2 0.131 mM−1S−1. This is related to the higher Ms of these nanoparticles in comparison to the Fe3O4@HPG-FA, and is associated with the high amounts of HPG coating on the Fe3O4@HPG surface, resulting in the reduction in the magnetic intensity of nanoparticles.

3. Discussion

Early detection is a critical factor for successful cancer therapy. In this regard, there are several methods for the early detection of cancer, among the most important of which is MRI, a highly sensitive method with low side effects. Since the possible side effects of the high magnetic field in MRI are still unknown, the clinical application of MRI with magnetic field less than 7T is FDA approved. Therefore, it is necessary to use a contrast agent, which could increase the sensitivity of MRI detection [10]. The unique properties of magnetic nanoparticles such as excellent biocompatibility and high magnetic behavior introduce them as an appropriate candidate for biomedical applications [48]. Consequently, the design and fabrication of biocompatible water-soluble iron oxide nanoparticles to be used as contrast agents have attracted a lot of attention, and significant attempts have been made in this field [49,50,51]. This study mainly aimed to compare the impact of two different coatings on the magnetic property of iron oxide nanoparticles using an MRI contrast agent.
Iron oxide magnetic nanoparticles were synthesized by using the polyol method. Then, the nanoparticles were coated with SiO2 and HPG, and folic acid as a targeting ligand was conjugated to the terminal hydroxyl groups of coating nanoparticles in a covalent manner. The findings of this study showed that coating Fe3O4 nanoparticles with SiO2 and HPG did not affect the viability of the MCF-7 cell line; while targeted nanoparticles, especially for the Fe3O4@HPG@FA, showed a partial cytotoxicity effect on the cells at high concentrations. This result has also been observed by other researchers [52]. The magnetic saturation was found at 33.86, 25.80, 10.77, and 1.66 emu/g−1 when HPG@SiO2, HPG@SiO2@HPG-FA, HPG, and HGP-FA were grafted to Fe3O4 nanoparticles, which were less than that of pure nanoparticles, with Ms of about 64.84 emu/g−1. These differences suggest that HPG coating could decrease Ms of nanoparticles more than SiO2@HPG. In addition, the reduction of nanoparticles’ magnetization due to the surface modifications has been confirmed by several studies [53,54].
Coating nanoparticles by HPG and SiO2@HPG produced an r 2   value of 0.029 and 8.87 mM−1S−1, respectively. These results demonstrated that coating nanoparticles with HPG significantly decreased the magnetic intensity of nanoparticles, due to the high polymerization and fewer number of Fe3O4 in the core in comparison to the silica coating nanoparticles. These results indicate that changing the surface coatings of nanoparticles could influence the transversal relaxivities ( r 2 ) [38]. That the relaxivity is a vital parameter for the estimation of the efficiency of a T2 contrast agent is quite well known. Hajesmaeelzadeh et al. reported that, by increasing the thickness of coating on iron oxide nanoparticles, there was an increase in their relaxivity. Moreover, they showed that with an increase in the nanoparticles size, the amount of r 2 relaxivity decreased. This result confirms that the type and amount of the coating affect the r 2 . values relaxivities [55]. According to Bitar et al., biocompatible SiO2 coating of nanoparticles makes them more dispersible in bio-media and easy to be functionalized using biomolecules for biomedicine research, too [56].
Furthermore, targeting the nanoparticles has an essential function in improving the particles selectivity against cancer cells. In addition, it could increase the accumulation of contrast agents needed for imaging in the targeted site [57]. The findings of this research reveal that the functionalization of HPG with FA leads to the attachment of nanoparticles to the folate receptors, which are expressed on the surface of MCF-7 cells that are later taken into the cell via receptor-mediated endocytosis (Figure 9). Nanoparticles lacking FA enter the MCF-7 cells using the non-specific penetration process. As a consequence, folic acid targeted nanoparticles have substantial r 2 relaxivities in comparison to the non-targeted one, just as what was reported in other studies [58,59]. As was predicted, Fe3O4@SiO2@HPG-FA nanoparticles, due to their higher magnetic intensity, have better r 2 relaxivities (23.25 mM−1S−1) in contrast to the Fe3O4@HPG targeted nanoparticles. Gholibegloo et al. reported that folic acid decorated magnetic nanoparticles have an r 2 value of about 54 mM−1S−1 [60]. However, they used cyclodextrin for the surface modification of nanoparticles as well as curcumin drug accompany with their MRI analysis, which could affect the MRI signal intensity. Moreover, when folic acid moieties were conjugated to the SiO2@HPG and HPG, the hydrophilicity of these nanoparticles also increased, leading to the elevation of their circulation time. Since particles with an r 2 value of more than 20 mM−1S−1 are well suited for the MRI contrast agent, Fe3O4@SiO2@HPG-FA with an r 2 value above 23 mM−1S−1, compared to non-targeting nanoparticles, possess more potential to be employed as contrast agents in MRI analysis.

4. Materials and Methods

4.1. Materials

Iron (III) acetylacetonate (Fe(acac)3), ethyl acetate, dicyclohexylcarbodiimide (DCC), and dimethyl aminopyridine (DMAP) were bought from Merck Co. (Munchen, Germany). Triethylene glycol (TREG) was obtained from Novachem (Calgary, Canada). Glycidol, dimethyl sulfoxide (DMSO), tetraethyl orthosilicate (TEOS), (3-Aminopropyl) triethoxysilane (APTES) and folic acid were bought from Sigma Aldrich Co. (St. Louis, MO, USA). For cell culture, the MCF7 cell line was obtained from Pasteur Institute (Tehran, Iran). Dulbecco’s modified Eagle’s medium (DMEM), phosphate buffer saline (PBS), and penamiicillin-streptomycin were purchased from BioIdia (Tehran, Iran), and fetal bovine serum (FBS) was obtained from Gibco Co. (Grand Island, NY, USA). 3-(4,5-dimethylthiazol-2)-2,5-diphenyltetrazolium bromide (MTT) was bought from Sigma Co. (Steinheim, Germany).

4.2. Fabrication of Fe3O4 Nanoparticles

Fe3O4 nanoparticles were prepared using the polyol method based on previous reports [61]. In summary, 0.053 g of Fe(acac)3 and 30 mL TREG were mixed using magnetic stirring. Then, the solution was slowly heated to 300 °C under N2 atmosphere, and it was kept at the reflux temperature for about 60 min. After cooling it to room temperature, 20 mL ethyl acetate was added to it while mixing the solution with a shaker. Then, nanoparticles were precipitated through a neodymium magnet and were washed with ethyl acetate three times, and the final precipitate was dried with a freeze-dryer (Vaco 5-ZIRBUS Tech, Harz, Germany) [62].

4.3. Synthesis of Polyglycerol Grafted Fe3O4

The anionic ring-opening polymerization of glycidol was carried out in accordance with the literature [33,62,63]. In brief, 1 mL of glycidol monomers was added to 30 mg Fe3O4 nanoparticles, and the mixture was sonicated at 25 °C for one h before being heated at 140 °C under N2 atmosphere for about 20 h. Then, it was cooled to room temperature, the blackish gel was poured into 10 mL DI water, and it was sonicated for 30 min. After dialysis, and the solution against DI-water (dialysis membrane 12 kDa) for 24 h, the nanoparticles were dried by freeze-dryer.

4.4. Fabrication of Fe3O4-Silica Core-Shell Nanoparticles

For other types of nanoparticles, Fe3O4 nanoparticles were coated by silica at first, and the silica-coated nanoparticles were functionalized by HPG. Briefly, the as-prepared Fe3O4 nanoparticles suspension was diluted with 60 mL of absolute ethanol with the help of sonication for 15 min, followed by the addition of 30 mL DI water and 25 mL NH4OH 28%. Then, 2 mL tetraethyl orthosilicate (TEOS) was added, and the mixture was handled by sonication at 40 °C for 5 h. The resulting product was collected by an external magnetic field prior to being washed with ethanol several times, with DI water, and acetone, and it was dried with a freeze-dryer. In the next step, 200 mg of Fe3O4-SiO2 was mixed with (3-Aminopropyl) triethoxysilane (APTES) (2 mL); then, the mixture was refluxed in dry toluene (100 mL) at 70 °C for 24 h, and the obtained amino-functionalized MNPs were isolated from the reaction mixture with a permanent external magnet before being washed with ethanol and DI-water several times; then, they were dried with a freeze-dryer [34,35].

4.5. Synthesis of SPION@SiO2@HPG

First, 100 mg of silica-coated magnetic nanoparticles were dispersed in 2 mL of a saturated potassium methoxide solution in methanol using bath sonication for 30 min, and the solution was stirred at room temperature for one h and refluxed at 80 °C for 2 h. In the end, the magnetic nanoparticles were separated with a magnet, washed with dry methanol three times, and dried with a freeze-dryer. Then, 2 mL glycidol was added to these deprotonated nanoparticles drop-wise for 15 min at 100 °C, and this mixture was refluxed at this temperature for four h. Then, it was cooled, and the contents were dissolved in methanol. Consequently, the product was separated with a magnet prior to being washed with methanol under sonication several times. The obtained product was dried with a freeze-dryer overnight in order to obtain the HPG-grafted silica-magnetic nanoparticles [42].

4.6. Folic Acid-Targeting of Nanoparticles

Conjugation of folic acid on Fe3O4@HPG and Fe3O4@SiO2@HPG was done according to the previous report [45]. Briefly, 5 mg FA and 100 mg Fe3O4 coated nanoparticles were added to 5 mL dry DMSO, and the mixture was sonicated for 2 min. Subsequently, 1.53 mg DMAP and 2.96 mg DCC were added to this mixture as intermediator. The resulting brown suspension was bath sonicated for 2 min and stirred at 50 °C for 36 h by magnetic stirring. After completing the process, the solution was dialyzed against DI-water (dialysis membrane 12–14 kDa) to remove DMAP, DCC, and unbounded FA. Finally, the solution was dried with a freeze-drier (Figure 10).

4.7. Characterization Techniques

FT-IR spectra were obtained in a transmission mode (JASCO, FT-IR-6300 (400–4000 cm−1), Tsukuba, Japan) to determine the surface modification of nanoparticles. The size and core-shell structure of nanoparticles were observed with transmission electron microscopy (JEOL JEM-ARM200CFEG UHR-TEM (Peabody, MA, USA) (equipped with STEM, Cs corrected STEM, EDS, Gatan Quantum GIF and Digital CCD Camera)). Magnetization measurements were carried out on a certain amount of ferrofluid by employing a vibrating sample magnetometer (VSM; MDKFT, Kosar Kashan Magnetics Corporation, IR, Kashan, Iran). This system specifies the amount and magnetization behavior of the sample as a function of the changes in the intensity of the constant magnetic field applied.

4.8. MTT Assay

The cytotoxicity of nanoparticles was determined using the MTT colorimetric assay. In this test, MCF-7 cell line, as a type of cancer cell with overexpression of FA receptor, was seeded in 96-well plates at a density of 5000 cells/well in 100 µL of medium, and it was incubated overnight at 37 °C in 5% CO2. After 24 h of incubation, the media of all wells were replaced with 100 µL of fresh media, holding different concentrations (25, 50, 100, and 200 µg/mL) of nanoparticles. All concentrations were replicated in three wells. After 24 and 48 h of incubation, the media were removed, and cells were washed with PBS twice. Then, 100 µL of pure medium was added to each well, followed by the addition of 10 µL of MTT solution (5 mg/mL in PBS), and the plates were incubated for four h at 37 °C. Then, the media were replaced by 100 µL DMSO and the plates were incubated for another 1 h. Finally, the wells absorbance was measured at 490 nm with a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA), in order to determine the viability of the cells.

4.9. In Vitro MR Imaging

MR imaging was carried out with a clinical 1.5 T MR Imager and a high-resolution head coil. MCF-7 cell line (250,000 cells per well) was incubated with different concentrations of SPION@HPG, SPION@HPG-FA, SPION@SiO2@HPG and SPION@SiO2@HPG-FA (0.0625, 0.125, 0.250 and 0.500 mM Fe) for 4 h. Then, the cells were washed with PBS twice to remove non-attached nanoparticles. The attached cells were then separated by adding trypsin and re-suspending in 1.5 mL gelatin. Determination of the T2 relaxation times was carried out by a multi-echo spine-echo sequence (repetition time (TR): 3000 ms; echo time (TE): 18–144 ms), slice thickness of 20 mm, and the field of view of 160 mm. The relaxation times for each sample were calculated by using in-house software (MATLAB 2016b) by non-linear least-squares fitting of appropriate exponential functions. Transverse relativities ( r 2 ) were calculated as the slope of the lines fitted by linear regression analysis (Microsoft EXCEL) to relaxation rates (1/T2).

5. Conclusions

In this research, the coating and targeting of iron oxide nanoparticles were compared and evaluated on their relaxivity, by conjugating HPG and SiO2@HPG as coating agents and the FA ligand as a targeting agent on the surface of nanoparticles. The findings of the research revealed that the amount of magnetic saturation for SiO2@HPG coating nanoparticles was higher than HPG coating. SiO2@HPG-FA targeted nanoparticles showed a high relaxivity of 23.25 mM−1S−1 compared to non-targeted SiO2@HPG nanoparticles. Moreover, HPG targeted nanoparticles have an r 2 value of about 0.131 mM−1S−1—considerably lower than SiO2@HPG@FA nanoparticles. Therefore, FA ligand could award this nanoparticle with targeting specificity to the tumor cells via receptor-mediated endocytosis. With these promising properties, Fe3O4@SiO2@HPG-FA nanoparticles have good potential to be used as MRI contrast agents in cells that have over-expression of folate receptors. However, future studies should be devoted to carry out in vivo test to understand its potential bio-applications.

Author Contributions

Conceptualization: A.Z. (Ali Zarrabi), I.J. and A.T.; Methodology: A.Z. (Atefeh Zarepour), H.H.S.H. and M.A.; Preparing first draft: M.A., H.H.S.H. and A.Z. (Atefeh Zarepour); Critical editing of manuscript: A.Z. (Ali Zarrabi) and P.M. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Mohammadinejad, R.; Dehshahri, A.; Sagar Madamsetty, V.; Zahmatkeshan, M.; Tavakol, S.; Makvandi, P.; Khorsandi, D.; Pardakhty, A.; Ashrafizadeh, M.; Ghasemipour Afshar, E.; et al. In vivo gene delivery mediated by non-viral vectors for cancer therapy. J. Control. Release 2020, 325, 249–275. [Google Scholar] [CrossRef]
  2. Makvandi, P.; Ghomi, M.; Padil, V.V.T.; Shalchy, F.; Ashrafizadeh, M.; Askarinejad, S.; Pourreza, N.; Zarrabi, A.; Nazarzadeh Zare, E.; Kooti, M.; et al. Biofabricated Nanostructures and Their Composites in Regenerative Medicine. ACS Appl. Nano Mater. 2020, 3, 6210–6238. [Google Scholar] [CrossRef]
  3. Wang, C.; Makvandi, P.; Zare, E.N.; Tay, F.R.; Niu, L. Advances in Antimicrobial Organic and Inorganic Nanocompounds in Biomedicine. Adv. Ther. 2020, 3, 2000024. [Google Scholar] [CrossRef]
  4. George, J.M.; Antony, A.; Mathew, B. Metal oxide nanoparticles in electrochemical sensing and biosensing: A review. Microchim. Acta 2018, 185, 358. [Google Scholar] [CrossRef] [PubMed]
  5. Mukherjee, S.; Madamsetty, V.S.; Bhattacharya, D.; Roy Chowdhury, S.; Paul, M.K.; Mukherjee, A. Recent advancements of nanomedicine in neurodegenerative disorders theranostics. Adv. Funct. Mater. 2020, 2003054. [Google Scholar] [CrossRef]
  6. Leng, F.; Liu, F.; Yang, Y.; Wu, Y.; Tian, W. Strategies on nanodiagnostics and nanotherapies of the three common cancers. Nanomaterials 2018, 8, 202. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Vallabani, N.V.S.; Singh, S.; Karakoti, A. Magnetic nanoparticles: Current trends and future aspects in diagnostics and nanomedicine. Curr. Drug Metab. 2019, 20, 457–472. [Google Scholar] [CrossRef]
  8. Hashemi, R.H.; Bradley, W.G.; Lisanti, C.J. MRI: The Basics; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2012; ISBN 1451148712. [Google Scholar]
  9. Issa, B.; Obaidat, I.M. Magnetic nanoparticles as MRI contrast agents. In Magnetic Resonance Imaging; IntechOpen: London, UK, 2019. [Google Scholar]
  10. Tocchio, S.; Kline-Fath, B.; Kanal, E.; Schmithorst, V.J.; Panigrahy, A. MRI evaluation and safety in the developing brain. Semin. Perinatol. 2015, 39, 73–104. [Google Scholar] [CrossRef] [Green Version]
  11. Lee, N.; Yoo, D.; Ling, D.; Cho, M.H.; Hyeon, T.; Cheon, J. Iron oxide based nanoparticles for multimodal imaging and magnetoresponsive therapy. Chem. Rev. 2015, 115, 10637–10689. [Google Scholar] [CrossRef]
  12. Zhao, X.; Zhao, H.; Chen, Z.; Lan, M. Ultrasmall superparamagnetic iron oxide nanoparticles for magnetic resonance imaging contrast agent. J. Nanosci. Nanotechnol. 2014, 14, 210–220. [Google Scholar] [CrossRef]
  13. Mahmoudi, M.; Serpooshan, V.; Laurent, S. Engineered nanoparticles for biomolecular imaging. Nanoscale 2011, 3, 3007–3026. [Google Scholar] [CrossRef] [PubMed]
  14. Na, H.B.; Song, I.C.; Hyeon, T. Inorganic nanoparticles for MRI contrast agents. Adv. Mater. 2009, 21, 2133–2148. [Google Scholar] [CrossRef]
  15. Qiao, R.; Yang, C.; Gao, M. Superparamagnetic iron oxide nanoparticles: From preparations to in vivo MRI applications. J. Mater. Chem. 2009, 19, 6274–6293. [Google Scholar] [CrossRef]
  16. Arsalani, N.; Fattahi, H.; Laurent, S.; Burtea, C.; Elst, L.V.; Muller, R.N. Polyglycerol-grafted superparamagnetic iron oxide nanoparticles: Highly efficient MRI contrast agent for liver and kidney imaging and potential scaffold for cellular and molecular imaging. Contrast Media Mol. Imaging 2012, 7, 185–194. [Google Scholar] [CrossRef]
  17. Reddy, L.H.; Arias, J.L.; Nicolas, J.; Couvreur, P. Magnetic nanoparticles: Design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. Chem. Rev. 2012, 112, 5818–5878. [Google Scholar] [CrossRef]
  18. Bigall, N.C.; Dilena, E.; Dorfs, D.; Beoutis, M.-L.; Pugliese, G.; Wilhelm, C.; Gazeau, F.; Khan, A.A.; Bittner, A.M.; Garcia, M.A. Hollow iron oxide nanoparticles in polymer nanobeads as MRI contrast agents. J. Phys. Chem. C 2015, 119, 6246–6253. [Google Scholar] [CrossRef]
  19. Albinali, K.E.; Zagho, M.M.; Deng, Y.; Elzatahry, A.A. A perspective on magnetic core-shell carriers for responsive and targeted drug delivery systems. Int. J. Nanomed. 2019, 14, 1707. [Google Scholar] [CrossRef] [Green Version]
  20. Wang, L.; Neoh, K.G.; Kang, E.-T.; Shuter, B. Multifunctional polyglycerol-grafted Fe3O4@ SiO2 nanoparticles for targeting ovarian cancer cells. Biomaterials 2011, 32, 2166–2173. [Google Scholar] [CrossRef]
  21. Wang, L.; Neoh, K.G.; Kang, E.T.; Shuter, B.; Wang, S. Superparamagnetic hyperbranched polyglycerol-grafted Fe3O4 nanoparticles as a novel magnetic resonance imaging contrast agent: An in vitro assessment. Adv. Funct. Mater. 2009, 19, 2615–2622. [Google Scholar] [CrossRef]
  22. Das, P.; Jana, N.R. Highly colloidally stable hyperbranched polyglycerol grafted red fluorescent silicon nanoparticle as bioimaging probe. ACS Appl. Mater. Interfaces 2014, 6, 4301–4309. [Google Scholar] [CrossRef]
  23. Moore, E.; Delalat, B.; Vasani, R.; McPhee, G.; Thissen, H.; Voelcker, N.H. Surface-initiated hyperbranched polyglycerol as an ultralow-fouling coating on glass, silicon, and porous silicon substrates. ACS Appl. Mater. Interfaces 2014, 6, 15243–15252. [Google Scholar] [CrossRef] [PubMed]
  24. Mahmoudi, M.; Sant, S.; Wang, B.; Laurent, S.; Sen, T. Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. Adv. Drug Deliv. Rev. 2011, 63, 24–46. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Yuan, P.; Ding, X.; Yang, Y.Y.; Xu, Q. Metal nanoparticles for diagnosis and therapy of bacterial infection. Adv. Healthc. Mater. 2018, 7, 1701392. [Google Scholar] [CrossRef] [PubMed]
  26. Kim, J.-E.; Shin, J.-Y.; Cho, M.-H. Magnetic nanoparticles: an update of application for drug delivery and possible toxic effects. Arch. Toxicol. 2012, 86, 685–700. [Google Scholar] [CrossRef] [PubMed]
  27. Laurent, S.; Forge, D.; Port, M.; Roch, A.; Robic, C.; Vander-Elst, L.; Muller, R.N. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem. Rev. 2008, 108, 2064–2110. [Google Scholar] [CrossRef] [PubMed]
  28. Amin, N.; Arajs, S. Morin temperature of annealed submicronic α-F2O3 particles. Phys. Rev. B 1987, 35, 4810. [Google Scholar] [CrossRef]
  29. Ortega, G.; Reguera, E. Biomedical applications of magnetite nanoparticles. In Materials for Biomedical Engineering; Elsevier: Amsterdam, The Netherlands, 2019; pp. 391–428. [Google Scholar]
  30. Chowdhuri, A.R.; Bhattacharya, D.; Sahu, S.K. Magnetic nanoscale metal organic frameworks for potential targeted anticancer drug delivery, imaging and as an MRI contrast agent. Dalton Trans. 2016, 45, 2963–2973. [Google Scholar] [CrossRef]
  31. Li, L.; Gao, F.; Jiang, W.; Wu, X.; Cai, Y.; Tang, J.; Gao, X.; Gao, F. Folic acid-conjugated superparamagnetic iron oxide nanoparticles for tumor-targeting MR imaging. Drug Deliv. 2016, 23, 1726–1733. [Google Scholar] [CrossRef]
  32. Zhang, Y.; Zhang, T.; Liu, M.; Kuang, Y.; Zu, G.; Zhang, K.; Cao, Y.; Pei, R. Aptamer-targeted magnetic resonance imaging contrast agents and their applications. J. Nanosci. Nanotechnol. 2018, 18, 3759–3774. [Google Scholar] [CrossRef]
  33. Mousavi, H.; Movahedi, B.; Zarrabi, A.; Jahandar, M. A multifunctional hierarchically assembled magnetic nanostructure towards cancer nano-theranostics. RSC Adv. 2015, 5, 77255–77263. [Google Scholar] [CrossRef]
  34. Torki, M.; Tangestaninejad, S.; Mirkhani, V.; Moghadam, M.; Mohammadpoor-Baltork, I. RuIII (OTf) SalophenCH2–NHSiO2–Fe: An efficient and magnetically recoverable catalyst for trimethylsilylation of alcohols and phenols with hexamethyldisilazane. Appl. Organomet. Chem. 2014, 28, 304–309. [Google Scholar] [CrossRef]
  35. Shahrestani, H.; Taheri-Kafrani, A.; Soozanipour, A.; Tavakoli, O. Enzymatic clarification of fruit juices using xylanase immobilized on 1, 3, 5-triazine-functionalized silica-encapsulated magnetic nanoparticles. Biochem. Eng. J. 2016, 109, 51–58. [Google Scholar] [CrossRef]
  36. Dadfar, S.M.; Roemhild, K.; Drude, N.I.; von Stillfried, S.; Knüchel, R.; Kiessling, F.; Lammers, T. Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications. Adv. Drug Deliv. Rev. 2019, 138, 302–325. [Google Scholar] [CrossRef] [PubMed]
  37. Yu, M.K.; Park, J.; Jon, S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2012, 2, 3. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Nordmeyer, D.; Stumpf, P.; Gröger, D.; Hofmann, A.; Enders, S.; Riese, S.B.; Dernedde, J.; Taupitz, M.; Rauch, U.; Haag, R. Iron oxide nanoparticles stabilized with dendritic polyglycerols as selective MRI contrast agents. Nanoscale 2014, 6, 9646–9654. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  39. Yang, X.; Wen, Y.; Wu, A.; Xu, M.; Amano, T.; Zheng, L.; Zhao, L. Polyglycerol mediated covalent construction of magnetic mesoporous silica nanohybrid with aqueous dispersibility for drug delivery. Mater. Sci. Eng. C 2017, 80, 517–525. [Google Scholar] [CrossRef]
  40. Makvandi, P.; Ali, G.W.; Della Sala, F.; Abdel-Fattah, W.I.; Borzacchiello, A. Biosynthesis and characterization of antibacterial thermosensitive hydrogels based on corn silk extract, hyaluronic acid and nanosilver for potential wound healing. Carbohydr. Polym. 2019, 223, 115023. [Google Scholar] [CrossRef]
  41. Makvandi, P.; Ali, G.W.; Della Sala, F.; Abdel-Fattah, W.I.; Borzacchiello, A. Hyaluronic acid/corn silk extract based injectable nanocomposite: A biomimetic antibacterial scaffold for bone tissue regeneration. Mater. Sci. Eng. C 2019, 107, 10195. [Google Scholar] [CrossRef]
  42. Landarani-Isfahani, A.; Taheri-Kafrani, A.; Amini, M.; Mirkhani, V.; Moghadam, M.; Soozanipour, A.; Razmjou, A. Xylanase immobilized on novel multifunctional hyperbranched polyglycerol-grafted magnetic nanoparticles: an efficient and robust biocatalyst. Langmuir 2015, 31, 9219–9227. [Google Scholar] [CrossRef]
  43. Mu, S.; Li, G.; Liang, Y.; Wu, T.; Ma, D. Hyperbranched polyglycerol-modified graphene oxide as an efficient drug carrier with good biocompatibility. Mater. Sci. Eng. C 2017, 78, 639–646. [Google Scholar] [CrossRef]
  44. Khelghati, N.; Rasmi, Y.; Farahmandan, N.; Sadeghpour, A.; Mir, S.M.; Karimian, A.; Yousefi, B. Hyperbranched polyglycerol β-cyclodextrin as magnetic platform for optimization of doxorubicin cytotoxic effects on Saos-2 bone cancerous cell line. J. Drug Deliv. Sci. Technol. 2020, 57, 101741. [Google Scholar] [CrossRef]
  45. Mostaghasi, E.; Zarepour, A.; Zarrabi, A. Folic acid armed Fe3O4-HPG nanoparticles as a safe nano vehicle for biomedical theranostics. J. Taiwan Inst. Chem. Eng. 2018, 82, 33–41. [Google Scholar] [CrossRef]
  46. Sun, C.; Sze, R.; Zhang, M. Folic acid-PEG conjugated superparamagnetic nanoparticles for targeted cellular uptake and detection by MRI. J. Biomed. Mater. Res. Part A 2006, 78, 550–557. [Google Scholar] [CrossRef] [PubMed]
  47. Cao, W.; Wang, X.; Song, L.; Wang, P.; Hou, X.; Zhang, H.; Tian, X.; Liu, X.; Zhang, Y. Folic acid-conjugated gold nanorod@ polypyrrole@ Fe3O4 nanocomposites for targeted MR/CT/PA multimodal imaging and chemo-photothermal therapy. RSC Adv. 2019, 9, 18874–18887. [Google Scholar] [CrossRef] [Green Version]
  48. Vallabani, N.V.S.; Singh, S. Recent advances and future prospects of iron oxide nanoparticles in biomedicine and diagnostics. 3 Biotech 2018, 8, 279. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  49. Bao, Y.; Sherwood, J.A.; Sun, Z. Magnetic iron oxide nanoparticles as T 1 contrast agents for magnetic resonance imaging. J. Mater. Chem. C 2018, 6, 1280–1290. [Google Scholar] [CrossRef]
  50. Lao, C.S.; Liu, J.; Gao, P.; Zhang, L.; Davidovic, D.; Tummala, R.; Wang, Z.L. ZnO nanobelt/nanowire Schottky diodes formed by dielectrophoresis alignment across Au electrodes. Nano Lett. 2006, 6, 263–266. [Google Scholar] [CrossRef] [Green Version]
  51. Hobson, N.J.; Weng, X.; Siow, B.; Veiga, C.; Ashford, M.; Thanh, N.T.K.; Schätzlein, A.G.; Uchegbu, I.F. Clustering superparamagnetic iron oxide nanoparticles produces organ-targeted high-contrast magnetic resonance images. Nanomedicine 2019, 14, 1135–1152. [Google Scholar] [CrossRef]
  52. Ghasemi, A.; Jafari, S.; Salehi, I. Synthesis and characterization of polyglycerol coated superparamagnetic iron oxide nanoparticles and cytotoxicity evaluation on normal human cell lines. Colloids Surf. A Physicochem. Eng. Asp. 2018, 551, 128–136. [Google Scholar] [CrossRef]
  53. Marín, T.; Montoya, P.; Arnache, O.; Calderón, J. Influence of surface treatment on magnetic properties of Fe3O4 nanoparticles synthesized by electrochemical method. J. Phys. Chem. B 2016, 120, 6634–6645. [Google Scholar] [CrossRef]
  54. Palomec-Garfias, A.F.; Jardim, K.V.; Sousa, M.H.; Márquez-Beltrán, C. Influence of polyelectrolyte chains on surface charge and magnetization of iron oxide nanostructures. Colloids Surf. A Physicochem. Eng. Asp. 2018, 549, 13–24. [Google Scholar] [CrossRef]
  55. Hajesmaeelzadeh, F.; Shanehsazzadeh, S.; Grüttner, C.; Daha, F.J.; Oghabian, M.A. Effect of coating thickness of iron oxide nanoparticles on their relaxivity in the MRI. Iran. J. Basic Med. Sci. 2016, 19, 166. [Google Scholar] [PubMed]
  56. Bitar, A.; Ahmad, N.M.; Fessi, H.; Elaissari, A. Silica-based nanoparticles for biomedical applications. Drug Discov. Today 2012, 17, 1147–1154. [Google Scholar] [CrossRef]
  57. Muhamad, N.; Plengsuriyakarn, T.; Na-Bangchang, K. Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: A systematic review. Int. J. Nanomed. 2018, 13, 3921. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  58. Zhang, H.; Li, J.; Hu, Y.; Shen, M.; Shi, X.; Zhang, G. Folic acid-targeted iron oxide nanoparticles as contrast agents for magnetic resonance imaging of human ovarian cancer. J. Ovarian Res. 2016, 9, 19. [Google Scholar] [CrossRef] [Green Version]
  59. Kevadiya, B.D.; Bade, A.N.; Woldstad, C.; Edagwa, B.J.; McMillan, J.M.; Sajja, B.R.; Boska, M.D.; Gendelman, H.E. Development of europium doped core-shell silica cobalt ferrite functionalized nanoparticles for magnetic resonance imaging. Acta Biomater. 2017, 49, 507–520. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  60. Gholibegloo, E.; Mortezazadeh, T.; Salehian, F.; Forootanfar, H.; Firoozpour, L.; Foroumadi, A.; Ramazani, A.; Khoobi, M. Folic acid decorated magnetic nanosponge: An efficient nanosystem for targeted curcumin delivery and magnetic resonance imaging. J. Colloid Interface Sci. 2019, 556, 128–139. [Google Scholar] [CrossRef] [PubMed]
  61. Yang, W.J.; Lee, J.H.; Hong, S.C.; Lee, J.; Lee, J.; Han, D.-W. Difference between toxicities of iron oxide magnetic nanoparticles with various surface-functional groups against human normal fibroblasts and fibrosarcoma cells. Materials 2013, 6, 4689–4706. [Google Scholar] [CrossRef] [Green Version]
  62. Zhao, L.; Chano, T.; Morikawa, S.; Saito, Y.; Shiino, A.; Shimizu, S.; Maeda, T.; Irie, T.; Aonuma, S.; Okabe, H. Hyperbranched polyglycerol-grafted superparamagnetic iron oxide nanoparticles: Synthesis, characterization, functionalization, size separation, magnetic properties, and biological applications. Adv. Funct. Mater. 2012, 22, 5107–5117. [Google Scholar] [CrossRef]
  63. Jahandar, M.; Zarrabi, A.; Shokrgozar, M.A.; Mousavi, H. Synthesis, characterization and application of polyglycerol coated Fe3O4 nanoparticles as a nano-theranostics agent. Mater. Res. Express 2015, 2, 125002. [Google Scholar] [CrossRef]
Sample Availability: Samples of the modified iron oxide are available from the authors.
Figure 1. FT-IR spectroscopy of (a) Fe3O4 (b) hyperbranched polyglycerol (HPG) grafted Fe3O4 and (c) Fe3O4@HPG-FA.
Figure 1. FT-IR spectroscopy of (a) Fe3O4 (b) hyperbranched polyglycerol (HPG) grafted Fe3O4 and (c) Fe3O4@HPG-FA.
Molecules 25 04053 g001
Figure 2. FT-IR spectroscopy of (a) Fe3O4@SiO2, (b) Fe3O4@SiO2@HPG, and (c) Fe3O4@SiO2@HPG-FA.
Figure 2. FT-IR spectroscopy of (a) Fe3O4@SiO2, (b) Fe3O4@SiO2@HPG, and (c) Fe3O4@SiO2@HPG-FA.
Molecules 25 04053 g002
Figure 3. Size distribution analysis of (a) Fe3O4, (b) Fe3O4@HPG, (c) Fe3O4@SiO2, and (d) Fe3O4@SiO2@HPG.
Figure 3. Size distribution analysis of (a) Fe3O4, (b) Fe3O4@HPG, (c) Fe3O4@SiO2, and (d) Fe3O4@SiO2@HPG.
Molecules 25 04053 g003
Figure 4. UHR-TEM analysis of (a) Fe3O4, (b) Fe3O4@HPG, (c) Fe3O4@SiO2, (d) Fe3O4@SiO2@HPG, and (e) Fe3O4@SiO2@HPG-FA.
Figure 4. UHR-TEM analysis of (a) Fe3O4, (b) Fe3O4@HPG, (c) Fe3O4@SiO2, (d) Fe3O4@SiO2@HPG, and (e) Fe3O4@SiO2@HPG-FA.
Molecules 25 04053 g004
Figure 5. Cytotoxicity evaluation of nanoparticles after (a) 24 h and (b) 48 h on the MCF-7 cell line.
Figure 5. Cytotoxicity evaluation of nanoparticles after (a) 24 h and (b) 48 h on the MCF-7 cell line.
Molecules 25 04053 g005
Figure 6. Magnetic behavior of (a) Fe3O4 nanoparticles (b) Fe3O4@SiO2@HPG (c) Fe3O4@SiO2@HPG-FA (d) Fe3O4@HPG (e) Fe3O4@HPG-FA.
Figure 6. Magnetic behavior of (a) Fe3O4 nanoparticles (b) Fe3O4@SiO2@HPG (c) Fe3O4@SiO2@HPG-FA (d) Fe3O4@HPG (e) Fe3O4@HPG-FA.
Molecules 25 04053 g006
Figure 7. T2-weighted image of MCF-7 cells after they are treated with different concentrations Fe of each contrast agent.
Figure 7. T2-weighted image of MCF-7 cells after they are treated with different concentrations Fe of each contrast agent.
Molecules 25 04053 g007
Figure 8. 1/T2 values as a function of concentration of (a) Fe3O4@HPG and Fe3O4@HPG-FA; (b) Fe3O4@SiO2@HPG and Fe3O4@SiO2@HPG-FA.
Figure 8. 1/T2 values as a function of concentration of (a) Fe3O4@HPG and Fe3O4@HPG-FA; (b) Fe3O4@SiO2@HPG and Fe3O4@SiO2@HPG-FA.
Molecules 25 04053 g008
Figure 9. Schematic representation of using nanoparticles for selective targeting of breast cancer cells.
Figure 9. Schematic representation of using nanoparticles for selective targeting of breast cancer cells.
Molecules 25 04053 g009
Figure 10. Synthesis and preparation of folic acid decorated nanoparticles.
Figure 10. Synthesis and preparation of folic acid decorated nanoparticles.
Molecules 25 04053 g010
Table 1. In vitro Transverse relativities ( r 2 ) of MRI contrast agents.
Table 1. In vitro Transverse relativities ( r 2 ) of MRI contrast agents.
r 2   [ mM 1 S 1 ]
Fe3O4@SiO2@HPG8.87
Fe3O4@SiO2@HPG-FA23.25
Fe3O4@HPG0.029
Fe3O4@HPG-FA0.131

Share and Cite

MDPI and ACS Style

Heydari Sheikh Hossein, H.; Jabbari, I.; Zarepour, A.; Zarrabi, A.; Ashrafizadeh, M.; Taherian, A.; Makvandi, P. Functionalization of Magnetic Nanoparticles by Folate as Potential MRI Contrast Agent for Breast Cancer Diagnostics. Molecules 2020, 25, 4053. https://doi.org/10.3390/molecules25184053

AMA Style

Heydari Sheikh Hossein H, Jabbari I, Zarepour A, Zarrabi A, Ashrafizadeh M, Taherian A, Makvandi P. Functionalization of Magnetic Nanoparticles by Folate as Potential MRI Contrast Agent for Breast Cancer Diagnostics. Molecules. 2020; 25(18):4053. https://doi.org/10.3390/molecules25184053

Chicago/Turabian Style

Heydari Sheikh Hossein, Hamid, Iraj Jabbari, Atefeh Zarepour, Ali Zarrabi, Milad Ashrafizadeh, Afrooz Taherian, and Pooyan Makvandi. 2020. "Functionalization of Magnetic Nanoparticles by Folate as Potential MRI Contrast Agent for Breast Cancer Diagnostics" Molecules 25, no. 18: 4053. https://doi.org/10.3390/molecules25184053

Article Metrics

Back to TopTop